Potential cancer outcome differences among psoriasis biologics found

Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern ...
Monthly Prescribing Reference

Prescribing Patterns for Initiation of Ustekinumab in Crohn Disease

The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the ...

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...
JD Supra

Biocon Announces FDA Approval of Ustekinumab Biosimilar

On December 1, 2024, Biocon announced that the FDA has approved YESINTEK™ (ustekinumab-kfce), a biosimilar to J&J’s STELARA®. YESINTEK is approved for the treatment of Crohn’s disease, Ulcerative ...
Monthly Prescribing Reference

Ustekinumab Effective for Long-Term Remission in Crohn’s Disease

Among randomized patients who entered the long-term extension trial period , 79.2% of patients receiving ustekinumab every 12 weeks and 87.1% of patients receiving ustekinumab every 8 weeks were in ...
Healio

Abatacept following ustekinumab withdrawal does not prevent psoriasis relapse

Please provide your email address to receive an email when new articles are posted on . Abatacept treatment after ustekinumab withdrawal did not prevent psoriasis relapse, according to a randomized ...
Yahoo Finance

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI ™ (ustekinumab-aekn) ...
Medindia

Ustekinumab Interaction with other Drugs

Ustekinumab is a monoclonal antibody, prescribed for psoriasis. The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bacillus calmette-guerin substrain connaught ...
MedPage Today

Risankizumab Beats Ustekinumab for Previously Treated Crohn's

Risankizumab (Skyrizi) resulted in more clinical remissions compared with ustekinumab (Stelara) in adults with moderate to severe Crohn's disease who had failed at least one previous tumor necrosis ...
Medscape

FDA Approves First Ustekinumab Biosimilar

The US Food and Drug Administration (FDA) has approved ustekinumab-auub (Wezlana) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. This is the first ...
TipRanks on MSN

Bristol-Myers Squibb’s Psoriasis Study: A Potential Game-Changer?

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...
Medscape

Ustekinumab Becomes Second Biologic Approved for PsA in Kids

The US Food and Drug Administration has approved the dual interleukin (IL)-12 and IL-23 inhibitor ustekinumab (Stelara) for the treatment of juvenile psoriatic arthritis (jPsA) in patients aged 6 ...